Viral complement control proteins for eye disorders
The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
1. A method of treating an eye disorder characterized by macular degeneration, choroidal neovascularization, retinal neovascularization, or ocular inflammation comprising:
administering an effective amount of a viral complement control protein (VCCP) or VCCP variant comprising a sequence at least 90% identical to SEQ ID NO: 2 to a subject in need thereof, wherein the VCCP or VCCP variant is locally administered to the eye or in the vicinity of the eye.
2. The method of claim 1 , wherein a VCCP is administered.
3. The method of claim 1 , wherein the VCCP is selected from the group consisting of vaccinia complement control protein (VCP), smallpox inhibitor of complement enzymes (SPICE), inflammation modulatory protein (IMP), and monkeypox viral complement control protein (MPVCP).
4. The method of claim 1 , wherein the VCCP or VCCP variant is locally administered in an ocular or periocular implant or insert or in a plurality of microparticles or nanoparticles.
5. The method of claim 1 , wherein the VCCP or VCCP variant is locally administered in a solution that forms a gel after introduction into the body.
6. The method of claim 1 , wherein the VCCP is a poxvirus complement control protein (PVCCP).
7. The method of claim 1 , wherein the VCCP is VCP or SPICE.
8. The method of claim 1 , wherein the VCCP or VCCP variant is administered by intravitreal injection.
9. A method of inhibiting neovascularization in the eye of a subject in need thereof comprising administering a VCCP or VCCP variant comprising a sequence at least 90% identical to SEQ ID NO: 2 to or in close proximity to the posterior segment of the subject's eye.
10. The method of claim 9 , wherein a VCCP is administered.
11. The method of claim 10 , wherein the VCCP is selected from the group consisting of VCP, SPICE, IMP, and MPVCP.
12. The method of claim 9 , wherein the VCCP or VCCP variant is administered in an ocular or periocular implant or insert or in a plurality of microparticles or nanoparticles.
13. The method of claim 9 , wherein the VCCP or VCCP variant is administered in a solution that forms a gel after introduction into the body.
14. The method of claim 9 , wherein the subject is suffering from age-related macular degeneration (ARMD).